ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AbbVie Inc (ABBV) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has a strong dividend history and stable cash flow, the recent financial performance shows a significant decline in net income and EPS. Additionally, the technical indicators and trading sentiment do not provide a clear bullish signal. The recent congressional selling activity further adds caution. It is better to hold off on buying until more favorable conditions emerge.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 45.628, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level of 224.896, with key resistance at 232.998 and support at 216.793. This suggests limited short-term upside potential.
AbbVie has declared a quarterly dividend of $1.73 per share, reflecting stable cash flow and a commitment to shareholder returns.
The company has increased its dividend by over 330% since 2013, showcasing financial health.
Revenue increased by 10.04% YoY in Q4 2025, indicating top-line growth.
Net income dropped significantly by -5775.00% YoY, and EPS declined by -5200.00% YoY in Q4 2025, raising concerns about profitability.
Congress members have sold shares recently, indicating cautious sentiment.
Analysts have mixed views, with some downgrades and price target reductions reflecting concerns about long-term growth and competition in key drug segments.
In Q4 2025, AbbVie reported a 10.04% YoY increase in revenue to $16.62 billion. However, net income dropped drastically by -5775.00% YoY to $1.82 billion, and EPS fell by -5200.00% YoY to $1.02. Gross margin improved slightly to 72.64%, up 2.47% YoY.
Analyst ratings are mixed. Piper Sandler raised the price target to $299 with an Overweight rating, citing strong drug development programs. However, UBS, Evercore, and Citi lowered their price targets, citing concerns about competition and long-term growth. Wolfe Research downgraded the stock to Peer Perform, reflecting cautious sentiment.
